ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Zhang LP, Zhang FN, 2010. Epidemiological and clinical analysis of 166 kala-azar cases. Parasites Infect Dis 18: 181–186.
-
2.
Killick-Kendrick R, 2010. Education is key to controlling visceral leishmaniasis. Bull World Health Organ 88: 11–12.
-
3.
Mondal S, Bhattacharya P, Ali N, 2010. Current diagnosis and treatment of visceral leishmaniasis. Expert Rev Anti Infect Ther 8: 919–944.
-
4.
Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F, 2011. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomized controlled trial. Lancet 377: 477–486.
-
5.
Kang X, Liu Y, Liu K, Lu X, 2009. Human leishmaniasis: a retrospective clinical analysis of 86 patients. Chin J Infect Chemother 9: 241–243.
-
6.
Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J, 2006. Liposomal amphotericin B for the treatment visceral leishmaniasis. Clin Infect Dis 43: 917–924.
-
7.
Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, 2010. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504–512.
-
8.
Thakur CP, 2001. A single high dose treatment of kala-azar with AmBisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 17: 67–70.
-
9.
Sinha PK, Roddy P, Palma PP, Kociejowski A, Lima MA, Rabi Das VN, Gupta J, Kumar N, Mitra G, Saint-Sauveur JF, Seena S, Balasegaram M, Parreño F, Pandey K, 2010. Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India. Am J Trop Med Hyg 83: 357–364.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 284 | 265 | 30 |
| Full Text Views | 273 | 16 | 1 |
| PDF Downloads | 69 | 10 | 1 |
Acute Renal Injury as a Result of Liposomal Amphotericin B Treatment in Sodium Stibogluconate Unresponsive Visceral Leishmaniasis
Songtao Zhao
Songtao Zhao
Institute of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing, China; Institute of Burn Research, Southwest Hospital, Third Military Medical University; State Key Laboratory of Trauma, Burns and Combined Injuries; Chongqing Key Laboratory for Diseases Proteomics, Chongqing, China
Search for other papers by Songtao Zhao in
Current site
Google Scholar
PubMed
Search for other papers by Songtao Zhao in
Current site
Google Scholar
PubMed
Dongxia Zhang
Dongxia Zhang
Institute of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing, China; Institute of Burn Research, Southwest Hospital, Third Military Medical University; State Key Laboratory of Trauma, Burns and Combined Injuries; Chongqing Key Laboratory for Diseases Proteomics, Chongqing, China
Search for other papers by Dongxia Zhang in
Current site
Google Scholar
PubMed
Search for other papers by Dongxia Zhang in
Current site
Google Scholar
PubMed
Ling Li
Ling Li
Institute of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing, China; Institute of Burn Research, Southwest Hospital, Third Military Medical University; State Key Laboratory of Trauma, Burns and Combined Injuries; Chongqing Key Laboratory for Diseases Proteomics, Chongqing, China
Search for other papers by Ling Li in
Current site
Google Scholar
PubMed
Search for other papers by Ling Li in
Current site
Google Scholar
PubMed
Qing Mao
Qing Mao
Institute of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing, China; Institute of Burn Research, Southwest Hospital, Third Military Medical University; State Key Laboratory of Trauma, Burns and Combined Injuries; Chongqing Key Laboratory for Diseases Proteomics, Chongqing, China
Search for other papers by Qing Mao in
Current site
Google Scholar
PubMed
Search for other papers by Qing Mao in
Current site
Google Scholar
PubMed
We report an unusual case of visceral leishmaniasis occurring in a patient from Sichuan China. The patient presented with a remitting fever, anemia, and pancytopenia. The case was confirmed as visceral leishmaniasis by microscopical detection of the Leishmania species amastigote in bone marrow aspirate. The patient was treated with 10 mg/kg/day of sodium stibogluconate for 5 days, with no therapeutic response. As a result, the patient was treated with liposomal amphotericin B (LAB) at 10 mg/day as an initial dosage. After treatment with an increasing drug dosage for 7 days, acute renal injury was evident as indicated by increased serum creatinine and urea nitrogen. LAB administration was discontinued until serum creatinine and serum urea nitrogen regressed on Day 15. Two maintenance treatments of 100 mg/day LAB were given on Days 19 and 26 (total 870 mg, 14.5 mg/kg). Bone marrow aspirate and clinical examination suggested total remission.
Author Notes
Authors' addresses: Songtao Zhao, Ling Li, and Qing Mao, Institute of Infectious Diseases, Southwest Hospital, Third Military Medical University, Chongqing, China, E-mails: zhaosongtao1995@163.com, a65409905@163.com, and qingmao@yahoo.com. Dongxia Zhang, Institute of Burn Research, State Key Laboratory of trauma, Burns and Combined Injury, Southwest Hospital, the Third Military Medical University, Chongqing, China, E-mail: dxzhangswh@hotmail.com.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Zhang LP, Zhang FN, 2010. Epidemiological and clinical analysis of 166 kala-azar cases. Parasites Infect Dis 18: 181–186.
-
2.
Killick-Kendrick R, 2010. Education is key to controlling visceral leishmaniasis. Bull World Health Organ 88: 11–12.
-
3.
Mondal S, Bhattacharya P, Ali N, 2010. Current diagnosis and treatment of visceral leishmaniasis. Expert Rev Anti Infect Ther 8: 919–944.
-
4.
Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F, 2011. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomized controlled trial. Lancet 377: 477–486.
-
5.
Kang X, Liu Y, Liu K, Lu X, 2009. Human leishmaniasis: a retrospective clinical analysis of 86 patients. Chin J Infect Chemother 9: 241–243.
-
6.
Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J, 2006. Liposomal amphotericin B for the treatment visceral leishmaniasis. Clin Infect Dis 43: 917–924.
-
7.
Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, 2010. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362: 504–512.
-
8.
Thakur CP, 2001. A single high dose treatment of kala-azar with AmBisome (amphotericin B lipid complex): a pilot study. Int J Antimicrob Agents 17: 67–70.
-
9.
Sinha PK, Roddy P, Palma PP, Kociejowski A, Lima MA, Rabi Das VN, Gupta J, Kumar N, Mitra G, Saint-Sauveur JF, Seena S, Balasegaram M, Parreño F, Pandey K, 2010. Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India. Am J Trop Med Hyg 83: 357–364.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 284 | 265 | 30 |
| Full Text Views | 273 | 16 | 1 |
| PDF Downloads | 69 | 10 | 1 |